Photographer: Akos Stiller / Bloomberg
Photographer: Akos Stiller / Bloomberg
Pfizer Inc. en BioNTech SE said the Covid-19 vaccine they are developing together is on track to be submitted for regulation by October, as it released additional data from an early-stage study.
The companies said the vaccine was well tolerated with mild to moderate fever in less than 20% of participants. The companies continue to analyze data from Phase 1 trials in the US and Germany, they said in a statement.
The confirmation of their October goal, first announced last month, the S&P helped lift 500 futures early on Friday as part of a drum of positive news about inoculation attempts that have the potential to end the threat of damaged lockdowns.
The timeline would make the vaccine one of the fastest moving in the world. Some analysts expect a fax to be approved for use in the US in November, a move that could give President Donald Trump a new foothold in the election.
Pfizer and BioNTech last month sought a $ 2 billion deal to deliver an initial 100 million doses of the vaccine to U.S. governments around the world seeking supplies of even more experimental candidates. hope of stabilizing local economies and stopping the spread of the virus that took nearly 800,000 lives worldwide.
(Updates with stock reaction in fourth paragraph)
.
